OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2017.6303 OL-0-0-6303 Articles miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer ShindoYoshitaro 1 HazamaShoichi 1 NakamuraYusuke 2 InoueYuka 1 KanekiyoShinsuke 1 SuzukiNobuaki 1 TakenouchiHiroko 1 TsunedomiRyouichi 1 NakajimaMasao 1 UenoTomio 1 TakedaShigeru 1 YoshinoShigefumi 1 OkunoKiyotaka 3 FujitaYusuke 4 HamamotoYoshihiko 4 KawakamiYutaka 5 OkaMasaaki 1 NaganoHiroaki 1 Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan Department of Medicine and Surgery, The University of Chicago, Chicago, IL 60637, USA Department of Surgery, Kinki University Faculty of Medicine, Osakasayama, Osaka 589-8511, Japan Department of Computer Science and Systems Engineering, Faculty of Engineering, Yamaguchi University, Ube, Yamaguchi 755-8611, Japan Division of Cellular Signaling, Institute for Advanced Medical Research; Keio University School of Medicine, Tokyo 160-8582, Japan Correspondence to: Professor Hiroaki Nagano, Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi 755-8505, Japan, E-mail: hnagano@yamaguchi-u.ac.jp 08 2017 02 06 2017 14 2 1355 1362 17022016 09032017 Copyright: © Shindo et al. 2017 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

MicroRNAs (miRNAs/miRs) regulate the levels of transcripts and serve a critical function in the regulation of tumor microenvironments. Therefore, miRNA levels in cancer tissues are thought to be potential biomarkers for immunotherapy. From a phase I trial of a vaccine treatment using 5 human leukocyte antigen (HLA)-A*2402-restricted peptides (registration no. UMIN000004948), colorectal cancer (CRC) tissues were obtained from 8 patients and normal colorectal tissues from 5 patients via surgery. From a phase II trial using the same peptides (registration no. UMIN000001791), CRC tissues were obtained from 16 patients from the HLA-A*2402-matched group and 10 patients from the HLA-A*2402-unmatched group. These tissues were used for miRNA microarray analysis. As the first step, cancer tissues from the phase I study were used and 10 candidate miRNAs were selected by comparing the miRNA expression between two groups; one with improved prognosis and the other with poor prognosis. The miRNAs were subsequently validated using the cases enrolled in the phase II study. Significantly improved prognoses were identified in 16 patients in the HLA-A*2402-matched group with high expression of miR-196b-5p and low expression of miR-378a-3p and miR-486-5p. There was no difference in prognosis in the 10 patients in the HLA-A*2402-unmatched group. Therefore, high miR-196b expression and low miR-378a-3p and miR-486-5p expression were indicated as useful biomarkers for prediction of the efficacy of vaccine treatment for patients with metastatic CRC. In a planned phase III study, expression levels of these 3 miRNAs (miR-196b-5p, miR-378a-3p and miR-486-5p) may be useful biomarkers for assessing patients who are likely to have an improved outcome following vaccination.

 microRNA predictive biomarker efficacy peptide vaccine colorectal cancer Introduction

MicroRNAs (miRNAs/miRs) are small, endogenous, non-coding RNAs composed of 18–25 nucleotides that regulate gene expression at the post-transcriptional level (1). Certain miRNAs act as oncogenes or tumor suppressors and are considered to be among the key regulators of cancer progression (2,3). Several previous studies have reported that miRNA levels in tumor tissues may be potential biomarkers for immunotherapy (4,5).

Active immunotherapy using tumor-associated antigen-derived epitope peptides (6,7), which aims to induce an in vivo response from tumor-specific cytotoxic T lymphocytes (CTLs), requires the preservation of the host immune system as indicated in the 2011 US Food and Drug Administration guidance report for therapeutic cancer vaccines (8). However, since advanced-stage patients with poor immune status are usually allowed to enroll into clinical studies in early-phase drug development, it is often difficult to evaluate the clinical benefit of these treatments (9). Therefore, it is necessary to identify predictive biomarkers to select patients who are likely to respond well and induce responses from specific CTLs to epitope peptides (10,11).

The authors of the present study previously reported a phase I study where 5 epitope peptides were administered to patients with advanced-stage colon cancer (6). Of these, 3 peptides were derived from oncoantigens: Ring finger protein 43 (RNF43) (12), 34 kDa translocase of the outer mitochondrial membrane (TOMM34) (13) and insulin growth factor-II mRNA binding protein 3 (KOC1, also known as IMP3) (14), and the remaining 2 peptides were derived from vascular endothelial growth factor receptors (VEGFRs) (15,16). A phase II study using the same vaccine regimen in combination with oxaliplatin-based chemotherapy was performed to further verify the safety and the potential of the vaccine to induce CTLs and to improve overall survival (OS) (17). In these studies, a high CTL response following vaccination and an injection site skin reaction were revealed to be potential markers for the outcome of vaccine treatment (6), and a low neutrophil/lymphocyte ratio was also a potential marker for improved survival time of vaccinated patients (17).

The purpose of the present study was to identify novel biomarkers in order to predict the efficacy of immunotherapies prior to treatment, and to use such information to select patients who are likely to exhibit improved treatment outcomes following vaccination. The results of a comprehensive miRNA microarray analysis of cancer tissues are presented in the present study, and a number of miRNAs were identified as novel biomarkers for predicting the efficiency of active immunotherapies.

 Materials and methods <sec> <title>Summary of the phase I study

The detailed protocol of the phase I study (UMIN clinical trial registration no. UMIN000004948) was described previously (6). Enrollment criteria were as follows: i) Histological confirmation of colorectal cancer (CRC) without surgical resection; ii) failure to respond to previous standard chemotherapy or intolerance to standard therapy and iii) positive DNA typing result for human leukocyte antigen (HLA)-A*2402.

The phase I study was primarily conducted to evaluate the safety and to investigate the recommended dose (RD) of these peptides. Good Manufacturing Practice grade RNF43-721 (NSQPVWLCL) (18), TOMM34-299 (KLRQEVKQNL) (13), KOC1 (IMP-3)-508 (KTVNELQNL) (19), VEGFR1-1084 (SYGVLLWEI) (20) and VEGFR2-169 (RFVPDGNRI) (21) peptides restricted with HLA-A*2402 were used. Dose escalation was performed in 3 patients with doses of 0.5, 1, and 3 mg for each peptide. Each peptide was mixed with 0.5 ml of incomplete Freund's adjuvant (IFA) and administered to patients subcutaneously into the thigh or axilla regions on days 1, 8, 15, and 22 of a 28-day treatment course. According to the results of this previous study, it was decided that the RD of each peptide was 3.0 mg, and a dose of 3.0 mg was administered to an additional 3 patients to confirm the safety of the peptides.

Next, a single injection of a cocktail of 5 peptides was performed, and this was expected to induce immune responses at the same level as separate injections of each of the 5 peptides. The cocktail of the 5 peptides (at the dose of 3 mg) was administered to 6 patients. A total of 8 out of 18 HLA-A*2402-positive CRC patients enrolled in the phase I clinical trial were available for miRNA analysis in the present study.

 Summary of the phase II study

To evaluate the clinical benefits of cancer vaccination treatment, a phase II trial (UMIN clinical trial registration no. UMIN000001791) was conducted using the previously described 5 peptides. The phase II trial was a non-randomized, HLA-A status double-blind study. The detailed protocol of this study was described previously (17). Briefly, the therapy consisted of a cocktail of 5 therapeutic epitope peptides (the same as those used in the phase I study), in addition to oxaliplatin-based chemotherapy. Although the peptides used in the phase II study were HLA-A*2402 restricted peptides, the same regime of peptide cocktail and oxaliplatin-based chemotherapy was administered to all enrolled patients, whose HLA-A status was double-blinded. The cocktail of (3 mg of each peptide) was mixed with 1.5 ml IFA and administered subcutaneously into the thigh or axilla regions once per week for 13 weeks. The vaccination schedule was subsequently reduced to once every 2 weeks. Vaccination was continued even if the disease progressed when the patient wished and a primary doctor who provided additional chemotherapies agreed. Enrollment criteria for the phase II study were as follows: i) ≥20 years old with histologically confirmed advanced CRC; ii) chemotherapy-naïve; iii) adequate function of organs and iv) a life expectancy of ≥3 months. Between February 2009 and November 2012, 96 chemotherapy-naïve CRC patients were enrolled and their HLA-A status was masked. Among the 96 patients who were enrolled in the phase II study, 26 cases were available for miRNA analysis in the present study.

 Sample collection

Among the 18 patients who participated in the phase I trial (6), tissues from 8 cases of CRC were obtained during surgery between October 2003 and June 2008. Of the patients, 4 were male and 4 were female, with an age range of 56–75 years and a mean age of 64 years. From these 8 patients, CRC tissues were obtained, and normal colorectal tissues were also obtained from surgical specimens of 5 patients between January 2004 and July 2006. Of the normal patients, 2 were male and 3 were female, with an age range of 59–75 years and a mean age of 66 years. Tissues were snap-frozen in liquid nitrogen and stored at −80°C. Similarly, CRC tissues were obtained from 26 patients who participated in the phase II trial of vaccine treatment in combination with oxaliplatin-based chemotherapy between October 2008 and September 2011 (17). Of these patients, 11 were male and 15 were female, with an age range of 47–82 years and a mean age of 67 years. CRC tissues were obtained from 16 cases from the HLA-A*2402-matched group and 10 cases from the HLA-A*2402-unmatched group.

All patients underwent resection of the cancer prior to phase I and II vaccine trials at Yamaguchi University Hospital (Yamaguchi, Japan). Written informed consent was obtained from all patients, and the present study was approved by the Institutional Ethics Review Boards of Yamaguchi University and was conducted in accordance with the Declaration of Helsinki.

 miRNA microarray

The median miRNA expression values in 34 cancer tissues were used as cut off values to classify patients into high or low expression group. Total RNA from CRC tissues and normal colorectal samples was analyzed by miRNA microarray. Total RNA was extracted from tissues using the mirVana miRNA Isolation kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. The concentration and purity of RNAs was assessed with a spectrophotometer and RNA integrity was verified using an Agilent RNA 6000 Nano kit (Agilent Technologies, Inc., Santa Clara, CA, USA). The optical density (OD) 260/OD280 ratios of each sample were within 2.00–2.10, which were accepted to be adequate for microarray analysis. The miRNA array was performed using 1 µg total RNA, the miRCURY LNA microRNA Array 6th generation (EXIQON; Qiagen, Inc., Valencia, CA, USA) and the GenePix 4000B (Molecular Devices, LLC; Sunnyvale, CA, USA). The relative intensity of each hybridization signal was evaluated using the Microarray Data Analysis tool (version 3.2; Filgen, Inc., Nagoya, Japan).

 Statistical analysis

Following the calculation of expression signals by log2 transformation of the normalized data, differentially expressed miRNAs were detected by using the fold-change value and Fisher index using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) according to the previously reported formula (22). Differences between groups were estimated using the Mann-Whitney U-test. Categorical variables were compared using χ2 and Fisher's exact tests. A Cox's proportional hazards model was used to estimate the hazard ratios for the treatment effect in relation to OS and miRNA expression, and OS was measured in days from the first vaccination until patient mortality (due to any cause). Survival curves were analyzed using the Kaplan-Meier method and the log-rank test. Statistical analyses were performed with JMP software (version 11; SAS Institute Inc., Cary, NC, USA) and GraphPad Prism software (version 5.0; GraphPad Software, Inc., San Diego, CA, USA). P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Selection of candidate miRNAs to predict the efficacy of vaccination

The expression profiles of 1,425 miRNAs in CRC tissues from 8 patients enrolled in the phase I study were analyzed. The characteristics of the 8 patients are listed in Table I. The patients were divided into 2 groups (responder and non-responder group) with 4 patients in each group. A responder is defined using the following criteria: i) Progression free survival (PFS) >150 days or ii) OS >300 days without additional chemotherapy. Criteria for non-responders were as follows: i) PFS <90 days and ii) OS <200 days.

On the basis of the relative comparison of hybridization signals, miRNAs with significant differences in expression between the responder and non-responder groups were selected. The 10 miRNAs with the most significant differences in expression between the two groups are listed in Table II.

 Comparison of miRNA expression levels between cancer tissues and normal colorectal tissues

miRNA microarray profiles of cancer tissues from the 8 patients enrolled in the phase I study and 26 patients enrolled in the phase II study were analyzed. Subsequently, the miRNA microarray profiles of the cancer tissues were compared with the microarray profiles of 5 normal colorectal tissues using the Mann-Whitney U-test. miR-196b-3p (P=0.011) and miR-196b-5p (P<0.001) were demonstrated to be upregulated compared with the normal tissues (Table III). In addition, miR-147b (P<0.001), miR-486-5p (P=0.003) and miR-378c (P=0.056; not significant) were downregulated in CRC tissues compared with normal tissues. A cut-off value for each miRNA (miR-142-5p, −196b-3p, −196b-5p, −147b, −320b, −378a-3p, −320e, −486-5p, −378c and −320a) was set at 1,400, 180, 450, 440, 6,000, 6,500, 5,800, 350, 1,200 and 6,500, respectively according to the median expression value (1,419, 184, 446, 435, 5,947, 6,496, 5,764, 350, 1,210, and 6,426, respectively) in 34 cancer tissues. The patients were classified into high or low expression groups based on a cut-off value of miRNA expression for subsequent analysis (Table III).

 Validation of candidate miRNA expression in patients enrolled in the phase II study

A total of 24 CRC tissues from the phase II study were analyzed using miRNA microarray. The profiles of the 26 patients are summarized in Table IV. A total of 10 candidate miRNAs were selected by analyzing cancer tissues in the phase I study (Table II) and the clinical outcome of 16 patients in the HLA-A*2402-matched group in the phase II study, where the same peptide vaccines were used in combination with oxaliplatin-based chemotherapy (Table V).

The expression levels of 10 candidate miRNAs were subsequently examined in 16 patients in the HLA-A*2402-matched group (Fig. 1). Significantly improved prognosis was observed in the patients with increased (>450) miR-196b-5p expression (hazard ratio=0.099, P=0.002, Table V; P=0.001, Fig. 1A), decreased (<6,500) miR-378a-3p expression (hazard ratio=0.223, P=0.025, Table V; P=0.022, Fig. 1B) and decreased (<350) miR-486-5p expression (hazard ratio=0.248, P=0.023, Table V; P=0.017; Fig. 1C) compared with the other patients with high or low expression of each miRNA. On the other hand, there was no difference in the prognoses in 10 patients in the HLA-A*2402-unmatched group according to expression levels of miR-196b-5p (P=0.271; Fig. 1D), miR-378a-3p (P=0.757; Fig. 1E) and miR-486-5p (P=0.562; Fig. 1F).

 Discussion

Due to the rapid and impressive progress made in the field of cancer immunology (23), a large number of novel vaccine approaches for the treatment of cancer are being developed (24,25). However, useful biomarkers that predict the clinical outcome of immunotherapy remain to be identified (10). In addition, only a small number of immunological or other biomarkers are available in clinical trials for immunotherapy (26). The identification of biomarkers would be useful for selecting appropriate patient populations for evaluation at earlier stages of clinical trials and for developing vaccines for cancer treatment (10,11). In the present study, the efficacy of novel biomarkers for immunotherapy was investigated by performing miRNA microarray analysis of cancer tissues and by comparing the clinical outcomes of phase I and II studies (6,17) testing a vaccine treatment for metastatic CRC using a cocktail of 5 HLA-A*2402 restricted peptides.

As the first step, miRNA expression patterns in 8 CRC tissues obtained from the patients in the phase I study were examined, and 10 candidate miRNAs were selected as potential predictive markers for the efficacy of immunotherapy by comparing miRNA expression of the responder and non-responder groups, one with improved prognosis and the other with poorer prognosis, using Fisher's ratio (Table II).

Subsequently, the expression levels of the 10 candidate miRNAs were examined in 34 cancer tissues (8 cases from the phase I study and 26 cases from the phase II study) and compared with the expression levels in 5 normal colorectal tissues. Upregulation of miR-196b-3p (P=0.011) and miR-196b-5p (P<0.001), and downregulation of miR-147b (P<0.001), miR-486-5p (P=0.003) and miR-378c (P=0.056; not significant) were observed in the cancer tissues (Table III). Cut-off values for each miRNA were set according to the median expression value in 34 cancer tissues (Table III), and patients were classified into 2 groups (high and low expression) for subsequent analysis (Table V).

The 10 candidate miRNAs were analyzed for association with prognoses of patients (n=26) enrolled in the phase II study. HLA-A*2402-restricted peptides were used in the phase II study. Therefore, the HLA-A*2402-matched group (n=16) was considered to be the immunological treatment group and the HLA-A*2402-unmatched group (n=10) the control group. Significantly improved prognoses were observed in the HLA-A*2402-matched group with increased (>450) miR-196b-5p expression (hazard ratio=0.099, P=0.002, Table V; log-rank test, P=0.001, Fig. 1A), decreased (<6,500) miR-378a-3p expression (hazard ratio=0.223, P=0.025, Table V; log-rank test, P=0.022, Fig. 1B) and decreased (<350) miR-486-5p expression (hazard ratio=0.248, P=0.023, Table V; log-rank test, P=0.017, Fig. 1C) compared with the other patients with high or low expression levels of each miRNA. However, there was no difference in prognosis in the HLA-A*2402-unmatched group (n=10) according to the expression of miR-196b-5p (P=0.271; Fig. 1D), miR-378a-3p (P=0.757; Fig. 1E) and miR-486-5p (P=0.562; Fig. 1F). These results indicated that these miRNAs may be used as biomarkers for immunotherapy.

The upregulation of miR-196b has previously been reported in lung adenocarcinoma, oral cancer, CRC, leukemia and lymphoma, and has been associated with the malignant phenotype of these types of cancer (27–30). By contrast, the results of the present study indicated that high miR-196b expression appeared to be associated with improved prognosis for patients treated with immunotherapy (Tables II and V; Fig. 1A). High miR-196b expression levels may be associated with the augmentation of the immune response to cancer, which may explain these paradoxical results. miR-196b has previously been reported to be a potential target of inflammatory signals, as it is known to be overexpressed in the inflammatory epithelial lesions of patients with Crohn's disease (31).

The cancer tissues used in the present study may contain not only cancer cells but also tumor infiltrating immune cells, as this has previously been suggested to be a biomarker for improved prognosis of CRC (32). The results of the present study indicated that high miR-196b expression may be used as a biomarker for predicting whether patients respond to immunotherapy, although the function of miR-196b requires clarification through further investigations.

miR-378a has been reported as a tumor suppressor and to be downregulated in CRC (33). However, the results of the present study indicated that reduced expression levels of miR-378a-3p were significantly associated with improved prognosis (Table V; Fig. 1C). miR-378a was also reported to promote cell survival, tumor growth and angiogenesis through repression of the expression of two tumor suppressors, SUFU negative regulator of hedgehog signaling and FUS RNA binding protein (34). As miR-378a is able to act as oncogene or a tumor suppressor, its function is complicated (33,34). Therefore, it is essential to further investigate the function of miR-378a-3p in the future.

miR-486 has been reported to be a cancer-suppressor miRNA, and it is often downregulated in a number of cancer types in multiple organs (35,36). Downregulation of miR-486 has been reported to contribute to tumor progression and metastasis (35). However, the results of the present study indicated that low expression of miR-486-5p was significantly associated with improved prognosis (Table V; Fig. 1E). Since miR-486 has been reported to sustain the activity of nuclear factor-κB (NF-κB) by disrupting multiple NF-κB-negative feedback loops (37) and suppressing the antitumor immunity of the host (38,39). Downregulation of miR-486 may reduce NF-κB expression and suppress immune-suppressive cells in the microenvironment of the tumor.

In conclusion, high miR-196b-5p, low miR-378a-3p and low miR-486-5p expression levels may be considered as novel biomarkers to predict the efficacy of immunotherapy. However, the results of the present study are preliminary, and the function of miRNAs in immune responses remain unclear. In a planned phase III study, it may be applicable to use these miRNAs as biomarkers to assess the selection of patients who may expect an improved outcome with the vaccine treatment.

 Acknowledgements

The present study was part of the research program of the Project for Development of Innovative Research on Cancer Therapeutics, the Japan Agency for Medical Research and Development. The authors would like to thank Dr. Takuya Tsunoda and Dr. Koji Yoshida (Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan) for their excellent advice and cooperation and providing all the peptides.

 Abbreviations miRNA/miR

microRNA

 HLA

human leukocyte antigen

 CRC

colorectal cancer

 CTL

cytotoxic T lymphocytes

 RNF43

ring finger protein 43

 TOMM34

34 kDa-translocase of the outer mitochondrial membrane

 KOC1

insulin-like growth factor-II mRNA binding protein 3

 VEGFR

vascular endothelial growth factor receptor

 OS

overall survival

 RD

recommended dose

 IFA

incomplete Freund's adjuvant

 NF-κB

nuclear factor-κB

 References ZaharieFMuresanMSPetrushevBBerceCGafencuGASeliceanSJurjACojocneanu-PetricRLisencuCIPopLAExosome-carried microRNA-375 inhibits cell progression and dissemination via Bcl-2 blocking in colon cancerJ Gastrointestin Liver Dis24435443201526697569 TakeyamaHYamamotoHYamashitaSWuXTakahashiHNishimuraJHaraguchiNMiyakeYSuzukiRMurataKDecreased miR-340 expression in bone marrow is associated with liver metastasis of colorectal cancerMol Cancer Ther13976985201410.1158/1535-7163.MCT-13-057124448820 KonnoYDongPXiongYSuzukiFLuJCaiMWatariHMitamuraTHosakaMHanleySJMicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cellsOncotarget560496062201410.18632/oncotarget.215725153722 AchbergerSAldrichWTubbsRCrabbJWSinghADTriozziPLCirculating immune cell and microRNA in patients with uveal melanoma developing metastatic diseaseMol Immunol58182186201410.1016/j.molimm.2013.11.01824370793 OkadaHKohanbashGLotzeMTMicroRNAs in immune regulation-opportunities for cancer immunotherapyInt J Biochem Cell Biol4212561261201010.1016/j.biocel.2010.02.00220144731 HazamaSNakamuraYTakenouchiHSuzukiNTsunedomiRInoueYTokuhisaYIizukaNYoshinoSTakedaKA phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcomeJ Transl Med1263201410.1186/1479-5876-12-6324612787 SuzukiNHazamaSUenoTMatsuiHShindoYIidaMYoshimuraKYoshinoSTakedaKOkaMA phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancerJ Immunother373642201410.1097/CJI.000000000000001224316554 U.S Department of Health and Human Services FaDAOctober2011U.S. Department of Health and Human Services, Food and Drug Administration, October 2011: Guidance for Industry. Clinical Considerations for Therapeutic Cancer Vaccines2011 NagorsenDThielEClinical and immunologic responses to active specific cancer vaccines in human colorectal cancerClin Cancer Res1230643069200610.1158/1078-0432.CCR-05-278816707603 CopierJWhelanMDalgleishABiomarkers for the development of cancer vaccines: Current statusMol Diagn Ther10337343200610.1007/BF0325621017154650 WhitesideTLImmune responses to cancer: Are they potential biomarkers of prognosis?Front Oncol3107201310.3389/fonc.2013.0010723730621 YagyuRFurukawaYLinYMShimokawaTYamamuraTNakamuraYA novel oncoprotein RNF43 functions in an autocrine manner in colorectal cancerInt J Oncol2513431348200415492824 ShimokawaTMatsushimaSTsunodaTTaharaHNakamuraYFurukawaYIdentification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug targetInt J Oncol29381386200616820880 KikuchiTDaigoYKatagiriTTsunodaTOkadaKKakiuchiSZembutsuHFurukawaYKawamuraMKobayashiKExpression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugsOncogene2221922205200310.1038/sj.onc.120628812687021 OlofssonBKorpelainenEPepperMSMandriotaSJAaseKKumarVGunjiYJeltschMMShibuyaMAlitaloKErikssonUVascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cellsProc Natl Acad Sci USA951170911714199810.1073/pnas.95.20.117099751730 MillauerBWizigmann-VoosSSchnurchHMartinezRMøllerNPRisauWUllrichAHigh affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesisCell72835846199310.1016/0092-8674(93)90573-97681362 HazamaSNakamuraYTanakaHHirakawaKTaharaKShimizuROzasaHEtohRSugiuraFOkunoKA phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)J Transl Med12108201410.1186/1479-5876-12-10824884643 UchidaNTsunodaTWadaSFurukawaYNakamuraYTaharaHRing finger protein 43 as a new target for cancer immunotherapyClin Cancer Res1085778586200410.1158/1078-0432.CCR-04-010415623641 SudaTTsunodaTDaigoYNakamuraYTaharaHIdentification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapyCancer Sci9818031808200710.1111/j.1349-7006.2007.00603.x17784873 IshizakiHTsunodaTWadaSYamauchiMShibuyaMTaharaHInhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1Clin Cancer Res1258415849200610.1158/1078-0432.CCR-06-075017020992 WadaSTsunodaTBabaTPrimusFJKuwanoHShibuyaMTaharaHRationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2Cancer Res6549394946200510.1158/0008-5472.CAN-04-375915930316 IizukaNOkaMYamada-OkabeHNishidaMMaedaYMoriNTakaoTTamesaTTangokuATabuchiHOligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resectionLancet361923929200310.1016/S0140-6736(03)12775-412648972 BoonTvan der BruggenPHuman tumor antigens recognized by T lymphocytesJ Exp Med183725729199610.1084/jem.183.3.7258642276 OkabeHSatohSKatoTKitaharaOYanagawaRYamaokaYTsunodaTFurukawaYNakamuraYGenome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progressionCancer Res6121292137200111280777 OkunoKSugiuraFItohKYoshidaKTsunodaTNakamuraYRecent advances in active specific cancer vaccine treatment for colorectal cancerCurr Pharm Biotechnol1314391445201210.2174/13892011280078499822339221 KijimaTHazamaSTsunedomiRTanakaHTakenouchiHKanekiyoSInoueYNakashimaMIidaMSakamotoKMicro RNA-6826 and −6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancerOncol Rep372330201727878288 LiXShiYYinZXueXZhouBAn eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinomaJ Transl Med12159201410.1186/1479-5876-12-15924893932 LuYCChangJTLiaoCTKangCJHuangSFChenIHHuangCCHuangYCChenWHTsaiCYOncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-JNK-TIMP1-MMP signaling pathwayMol Cancer13218201410.1186/1476-4598-13-21825233933 GeJChenZLiRLuTXiaoGUpregulation of microRNA-196a and microRNA-196b cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal cancerCancer Cell Int14128201410.1186/s12935-014-0128-225525411 PanYMengMZhangGHanHZhouQOncogenic microRNAs in the genesis of leukemia and lymphomaCurr Pharm Des2052605267201410.2174/138161282066614012821172424479800 ChenWXRenLHShiRHImplication of miRNAs for inflammatory bowel disease treatment: Systematic reviewWorld J Gastrointest Pathophysiol56370201424891977 GalonJMlecnikBBindeaGAngellHKBergerALagorceCLugliAZlobecIHartmannABifulcoCTowards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursJ Pathol232199209201410.1002/path.428724122236 ZhangGJZhouHXiaoHXLiYZhouTMiR-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancerBMC Cancer14109201410.1186/1471-2407-14-10924555885 LeeDYDengZWangCHYangBBMicroRNA-378 promotes cell survival, tumor growth and angiogenesis by targeting SuFu and Fus-1 expressionProc Natl Acad Sci USA1042035020355200710.1073/pnas.070690110418077375 ChenHRenCHanCWangDChenYFuDExpression and prognostic value of miR-486-5p in patients with gastric adenocarcinomaPLoS One10e0119384201510.1371/journal.pone.011938425793394 WangJTianXHanRZhangXWangXShenHXueLLiuYYanXShenJDownregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancerOncogene3311811189201410.1038/onc.2013.4223474761 SongLLinCGongHWangCLiuLWuJTaoSHuBChengSYLiMLiJmiR-486 sustains NF-κB activity by disrupting multiple NF-κB-negative feedback loopsCell Res23274289201310.1038/cr.2012.17423247627 FisherDTAppenheimerMMEvansSSThe two faces of IL-6 in the tumor microenvironmentSemin Immunol263847201410.1016/j.smim.2014.01.00824602448 GajewskiTFSchreiberHFuYXInnate and adaptive immune cells in the tumor microenvironmentNat Immunol1410141022201310.1038/ni.270324048123

Overall survival of the 16 patients in the HLA-A*2402-matched group and the 10 patients in the HLA-A*2402-unmatched group treated in the phase II study, according to expression levels of miRNAs, as determined by Kaplan-Meier analysis. (A) miR-196b-5p and HLA-A*2402-matched group; (B) miR-378a-3p and HLA-A*2402-matched group; (C) miR-486-5p and HLA-A*2402-matched group; (D) miR-196b-5p and HLA-A*2402-unmatched group; (E) miR-378a-3p and HLA-A*2402-unmatched group and (F) miR-486-5p and HLA-A*2402-unmatched group. The solid line indicates high miRNA expression, and the dashed line indicates low miRNA expression. Statistical analysis was performed using the log-rank test. HLA, human leukocyte antigen; miRNA/miR, microRNA.

Patient characteristics and outcomes of the phase I study.

Prognosis
Patient no. Dose of peptide (mg) Age Sex Sites of disease Previous treatmentsa Response PFS (days) OS (days) Status Treatments following vaccination Responder or non-responderb
1 0.5 56 M LN IRI, OX, FU CR 2,150 2,150 A None Responder
2 0.5 72 F Lungs, bone IRI, OX, FU PD 60 191 D None Non-responder
3 0.5 75 M Liver, lung IRI, OX, FU SD 158 406 D OX, FU, BEV Responder
4 1.0 59 F Dissemi. IRI, OX, FU PD 36 80 D None Non-responder
6 1.0 69 M Lungs, LN IRI, OX, FU PD 62 110 D None Non-responder
9 3.0 59 M Lungs IRI, OX, FU SD 221 885 D None Responder
14 3.0 (mix) 65 F Dissemi. IRI, OX, FU PD 50 342 D None Responder
19 3.0 (mix) 58 F Liver, dissemi. OX, FU, BEV PD 37 52 D None Non-responder

Operation was performed for all patients for the resection of primary lesions.

Criteria for responders were as follows: i) PFS >150 days or ii) OS >300 days without additional chemotherapy. Criteria for non-responders were as follows: i) PFS <90 days and ii) OS <200 days. LN, lymph nodes; Dissemi, peritoneal dissemination; PFS, progression free survival; OS, overall survival; IRI, irinotecan; OX, oxaliplatin; FU, fluoropyrimidine; BEV, bevacizumab; D, succumbed to disease; A, alive; CR, complete response; SD, stable disease; PD, progressive disease.

miRNA expression of cancer tissues of patients in the phase I study.

Signal intensity in cancer tissues
Responder (n=4) Non-responder (n=4)
Rank Name of miRNA Mean SD Mean SD Log2 ratio >0.8 Fisher's ratio P-valuea miRNA expression in the responder group
  1 hsa-miR-142-5p 1,606.3 275.3 3,697.8 1,734.8 −1.2 4.8 0.055 Low
  2 hsa-miR-196b-3p 295.7 83.2 164.2 26.1 0.8 4.5 0.024 High
  3 hsa-miR-196b-5p 678.0 381.6 172.0 56.5 2.0 3.6 0.039 High
  4 hsa-miR-147b 332.9 86.0 778.3 366.0 −1.2 3.4 0.090 Low
  5 hsa-miR-320b 4480.4 2085.6 8208.7 1799.7 −0.9 3.4 0.035 Low
  6 hsa-miR-378a-3p 5711.6 2043.9 9709.1 2499.3 −0.8 3.0 0.048 Low
  7 hsa-miR-320e 3293.1 1831.7 6073.7 1557.0 −0.9 2.9 0.060 Low
  8 hsa-miR-486-5p 289.0 53.4 516.7 244.3 −0.8 2.7 0.119 Low
  9 hsa-miR-378c 950.8 522.4 1978.7 732.5 −1.1 2.6 0.062 Low
10 hsa-miR-320a 4823.1 2574.0 9183.3 2923.4 −0.9 2.4 0.066 Low

Responder vs. non-responder. miRNA/miR, microRNA; SD, standard deviation; hsa, Homo sapiens.

miRNA expression of cancer tissues and normal colorectal tissues.

Signal intensity in cancer tissues (n=34) Signal intensity in normal colorectal tissues (n=5)
miR rank in the phase I study Name of miRNA Mean ± SD (n=34) Median Cut off value Mean ± SD (n=5) Median P-valuea
1 miR-142-5p 1,874.4±1406.5 1,419 <1400 2,782.8±3284.3 1,129 0.850
2 miR-196b-3p 212.9±96.3 184 >180 119.2±15.2 119 0.011
3 miR-196b-5p 627.0±615.2 446 >450 105.4±10.5 106 <0.001
4 miR-147b 500.5±227.6 435 <440 1243.8±188.7 1213 <0.001
5 miR-320b 6079.2±2127.6 5947 <6000 6792.0±2861.0 5676 0.850
6 miR-378a-3p 6575.0±2459.3 6496 <6500 8035.4±2335.6 9575 0.200
7 miR-320e 5981.1±2301.0 5764 <5800 4623.2±1081.0 4390 0.159
8 miR-486-5p 358.8±115.1 350 <350 528.6±124.0 483 0.003
9 miR-378c 1341.7±702.0 1210 <1200 2062.2±707.0 2056 0.056
10 miR-320a 6647.1±2666.4 6426 <6500 7695.8±2724.2 6413 0.437

Normal vs. cancer tissues. miRNA/miR, microRNA; SD, standard deviation.

Characteristics of patients in the phase II study.

HLA-A*2402
Characteristics Matched (n=16) Unmatched (n=10) P-value
Sex
  Male 5 6 >0.05
  Female 11 4
Age
  Mean 69.8 63.5 >0.05
  Range 58–82 47–76
Unresectable site
  Liver 8 7 >0.05
  Lung 5 5
  Dissemination 1 2
  Bone 0 1
  Lymph node 3 3
  Other 1 1
Resection of primary lesion
  Yes 16 10
  No 0 0
Chemotherapy
  FOLFOX 15 10 >0.05
  XELOX 1 0
  Bevacizumab 0 1
Location of cancer
  Colon 12 5 >0.05
  Rectum 4 5

FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; XELOX, capecitabine and oxaliplatin; HLA, human leukocyte antigen.

Overall survival according to miRNA expression (n=16, patients with HLA-A*2402).

Number of patients
miR rank in the phase I study Name of microRNA Cut off valuea Low expression High expression Hazard ratio 95% CI P-value
  1 miR-142-5p <1,400 8 8 0.785 0.243–2.534 0.678
  2 miR-196b-3p >180 7 9 0.447 0.136–1.463 0.178
  3 miR-196b-5p >450 7 9 0.099 0.014–0.441 0.002
  4 miR-147b <440 8 8 0.320 0.084–1.041 0.059
  5 miR-320b <6,000 10 6 0.933 0.292–3.219 0.908
  6 miR-378a-3p <6,500 9 7 0.223 0.046–0.832 0.025
  7 miR-320e <5,800 7 9 0.624 0.165–2.000 0.435
  8 miR-486-5p <350 9 7 0.248 0.070–0.820 0.023
  9 miR-378c <1,200 5 11 0.630 0.139–2.125 0.475
10 miR-320a <6,500 9 7 0.706 0.217–2.308 0.556

Cut-off values based on the median expression value in 34 cancer tissues were used to assess miRNA expression. miRNA/miR, microRNA; HLA, human leukocyte antigen; SD, standard deviation; has, Homo sapiens; CI, confidence interval.